Placebo News and Research

RSS

Celebrex suspension

The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).

19 Dec 2004

Obesity drug codenamed AOD9604 highly successful in trials

An Australian-owned obesity drug, developed by Melbourne-based biotechnology company Metabolic Pharmaceuticals Limited, is set to enter final human trials next year after successfully completing a Phase 2b human trial which proved that the drug induces weight loss and is very well tolerated with no evidence of the side effects commonly experienced with existing obesity drugs.

16 Dec 2004

Vaccinating mice against Lyme disease could help reduce the risk of transmission of the disease to humans

Vaccinating large populations of white-footed mice against the bacterium that causes Lyme disease could help reduce the risk of transmission of the disease to humans, says a study supported by the National Institute of Allergy and Infectious Diseases (NIAID).

14 Dec 2004

Detrol LA significantly reduces symptoms of overactive bladder

Pfizer today announced results of a comprehensive six-year review of efficacy and safety data for Detrol LA (tolterodine tartrate extended release capsules) indicating that Detrol LA significantly reduces symptoms of overactive bladder (OAB) with a low occurrence of side effects, and should be considered first-line therapy.

13 Dec 2004

Successful human trial of obesity drug that mimicks metabolic effects of growth hormone

The AOD9604 molecule is a small orally active peptide modelled on one section of the human growth hormone molecule. Growth hormone naturally occurs in the body and has profound stimulatory effects on fat metabolism, with levels of the hormone typically becoming suppressed in the obese state.

13 Dec 2004

FDA accepts Genmab's Investigational New Drug Application for active rheumatoid arthritis treatment

Genmab announced today the US Food and Drug Administration (FDA) accepted its Investigational New Drug Application (IND) to start a Phase I/II dose escalation trial for HuMax-CD20 to treat patients with active rheumatoid arthritis (RA) who have failed one treatment with one or more disease modifying anti-rheumatic drugs (DMARDs).

13 Dec 2004

Folate supplementation during pregnancy may increase a mother's long-term risk of breast cancer

Preliminary data published in the BMJ suggest that folate supplementation during pregnancy may increase a mother's long-term risk of breast cancer. Although this may be a chance finding, the results require confirmation, say the authors.

13 Dec 2004

Excellent news for the many people who suffer from high blood pressure

An international trial comparing blood-pressure lowering treatments has been stopped early due to the significantly better performance of one of the treatments in the trial.

8 Dec 2004

New advances in sickle cell disease

Excruciating pain episodes, recurrent pneumonias, strokes, severe infections, chronic hemolytic anemia, and secondary pulmonary hypertension are common complications of sickle cell disease, a life-threatening inherited defect in blood that causes normally disc-shaped red blood cells to take on a sickle shape.

6 Dec 2004

Review findings released on the safety of antidepressants (SSRI's)

The Medicines and Healthcare products Regulatory Agency (MHRA) issued new advice to patients and doctors about the group of antidepressants known as SSRI's, today.

6 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

Methylphenidate improves attention, behavior of children surviving acute lymphoblastic leukemia, brain tumors

Children who suffer from behavioral and learning problems after their central nervous systems have been exposed to chemotherapy or radiation appear to benefit from treatment with methylphenidate (MPH), the drug commonly known by the brand name Ritalin®.

4 Dec 2004

New devices for people who suffer dry mouth or lack of saliva

For dry mouth sufferers Saliwell’s innovative patented devices brings welcome relief by restoring natural saliva production through electro-stimulation.

2 Dec 2004

Higher incidence of rejection following early steroid withdrawal

A new study on early steroid withdrawal following liver transplantation found that there was a higher incidence of rejection and a lower incidence of glucose intolerance necessitating treatment for diabetes.

1 Dec 2004

Novel anti-obesity compound shows promise for treatment of obesity

Arena Pharmaceuticals announced today results from the dosing phase of its Phase 1b clinical trial of APD356, an orally administered small molecule designed to regulate satiety (and perhaps metabolism) for the treatment of obesity.

30 Nov 2004

Adding a commonly used dietary supplement to antidepressants may improve treatment

Massachusetts General Hospital (MGH) researchers have found that adding the nutritional supplement SAMe to a standard antidepressant may be helpful to patients who have not responded to single-drug treatment for clinical depression.

30 Nov 2004

FDA approves Combunox tablets for the short-term treatment of acute, moderate to severe pain

Forest Laboratories have announced that Combunox (Oxycodone HCl and Ibuprofen) Tablets (CII), the first and only fixed-dose combination of the opioid oxycodone HCl (5 mg) and the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen (400 mg), was approved by the U.S. Food and Drug Administration (FDA) for the short-term management of acute, moderate to severe pain.

29 Nov 2004

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

Topical cream alternative to Vioxx

A clinical study recently published in The Journal of Rheumatology concludes that a topical cream consisting of a blend of natural oils called cetylated fatty acids significantly increased range of motion and physical performance in patients with osteoarthritis of the knee with no reported side effects.

24 Nov 2004

Testosterone has both a physiological and a psychological impact on women’s sexuality

A recently published dissertation from the Karolinska Institutet in Sweden shows that testosterone has both a physiological and a psychological impact on women’s sexuality.

23 Nov 2004

Placebo News and Research

Celebrex suspension

Obesity drug codenamed AOD9604 highly successful in trials

Vaccinating mice against Lyme disease could help reduce the risk of transmission of the disease to humans

Detrol LA significantly reduces symptoms of overactive bladder

Successful human trial of obesity drug that mimicks metabolic effects of growth hormone

FDA accepts Genmab's Investigational New Drug Application for active rheumatoid arthritis treatment

Folate supplementation during pregnancy may increase a mother's long-term risk of breast cancer

Excellent news for the many people who suffer from high blood pressure

New advances in sickle cell disease

Review findings released on the safety of antidepressants (SSRI's)

Single dose phase I data on CG53135 for the prevention of oral mucositis

Methylphenidate improves attention, behavior of children surviving acute lymphoblastic leukemia, brain tumors

New devices for people who suffer dry mouth or lack of saliva

Higher incidence of rejection following early steroid withdrawal

Novel anti-obesity compound shows promise for treatment of obesity

Adding a commonly used dietary supplement to antidepressants may improve treatment

FDA approves Combunox tablets for the short-term treatment of acute, moderate to severe pain

FDA approval of Tysabri, for the treatment of multiple sclerosis

Topical cream alternative to Vioxx

Testosterone has both a physiological and a psychological impact on women’s sexuality

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News